Dr. Mark Gold, MD

NPI: 1578504593
Total Payments
$533,982
2023 Payments
$30,000
Companies
7
Transactions
265

Payment Breakdown by Category

Consulting$348,966 (65.4%)
Other$128,725 (24.1%)
Travel$48,982 (9.2%)
Food & Beverage$7,309 (1.4%)

Payments by Nature

Nature of Payment Amount Transactions Share
Consulting Fee $348,966 166 65.4%
Honoraria $66,850 14 12.5%
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $61,875 17 11.6%
Travel and Lodging $48,982 30 9.2%
Food and Beverage $7,309 31 1.4%
Unspecified $0 7 0.0%

Payments by Type

General
$533,982
258 transactions
Ownership
$0
7 transactions

Top Paying Companies

Company Total Records Latest Year
Emergent BioSolutions Inc. $290,725 167 $0 (2022)
Magstim Group Inc. $90,658 12 $0 (2019)
AXOGEN $73,232 35 $0 (2023)
ADAPT PHARMA INC. $53,591 23 $0 (2018)
Welcony Inc. $13,747 2 $0 (2020)
VIEWRAY TECHNOLOGIES INC $12,028 25 $0 (2018)

Payment History by Year

Year Amount Transactions Top Company
2023 $30,000 2 AXOGEN ($30,000)
2022 $58,330 10 Emergent BioSolutions Inc. ($58,330)
2021 $70,255 21 Emergent BioSolutions Inc. ($69,996)
2020 $163,146 143 Emergent BioSolutions Inc. ($149,399)
2019 $33,000 5 Magstim Group Inc. ($20,000)
2018 $73,656 27 ADAPT PHARMA INC. ($53,591)
2017 $105,596 57 Magstim Inc. ($50,640)

All Payment Transactions

265 individual payment records from CMS Open Payments — Page 1 of 11

Date Company Product Nature Form Amount Type
12/20/2023 AXOGEN Avance Nerve Graft (Device), AxoGuard Nerve Connector, AxoGuard Nerve Protector Consulting Fee Cash or cash equivalent $15,000.00 General
Category: Neurology
06/14/2023 AXOGEN Avance Nerve Graft (Device), AxoGuard Nerve Connector, AxoGuard Nerve Protector Consulting Fee Cash or cash equivalent $15,000.00 General
Category: Neurology
12/07/2022 Emergent BioSolutions Inc. Consulting Fee Cash or cash equivalent $5,833.00 General
12/07/2022 Emergent BioSolutions Inc. Consulting Fee Cash or cash equivalent $5,833.00 General
09/07/2022 Emergent BioSolutions Inc. Consulting Fee Cash or cash equivalent $5,833.00 General
09/07/2022 Emergent BioSolutions Inc. Consulting Fee Cash or cash equivalent $5,833.00 General
06/22/2022 Emergent BioSolutions Inc. Consulting Fee Cash or cash equivalent $5,833.00 General
06/22/2022 Emergent BioSolutions Inc. Consulting Fee Cash or cash equivalent $5,833.00 General
06/22/2022 Emergent BioSolutions Inc. Consulting Fee Cash or cash equivalent $5,833.00 General
05/04/2022 Emergent BioSolutions Inc. Consulting Fee Cash or cash equivalent $5,833.00 General
03/02/2022 Emergent BioSolutions Inc. Consulting Fee Cash or cash equivalent $5,833.00 General
03/02/2022 Emergent BioSolutions Inc. Consulting Fee Cash or cash equivalent $5,833.00 General
12/15/2021 Emergent BioSolutions Inc. Consulting Fee Cash or cash equivalent $5,833.00 General
12/15/2021 Emergent BioSolutions Inc. Consulting Fee Cash or cash equivalent $5,833.00 General
12/14/2021 AXOGEN Avance Nerve Graft (Device) Food and Beverage Cash or cash equivalent $21.54 General
Category: Neurology
12/13/2021 AXOGEN Avance Nerve Graft (Device) Food and Beverage Cash or cash equivalent $35.59 General
Category: Neurology
12/10/2021 AXOGEN Avance Nerve Graft (Device) Food and Beverage Cash or cash equivalent $46.34 General
Category: Neurology
12/10/2021 AXOGEN Avance Nerve Graft (Device) Food and Beverage Cash or cash equivalent $25.06 General
Category: Neurology
12/08/2021 AXOGEN Avance Nerve Graft (Device) Food and Beverage Cash or cash equivalent $24.69 General
Category: Neurology
10/20/2021 Emergent BioSolutions Inc. Consulting Fee Cash or cash equivalent $5,833.00 General
10/20/2021 Emergent BioSolutions Inc. Consulting Fee Cash or cash equivalent $5,833.00 General
10/20/2021 Emergent BioSolutions Inc. Consulting Fee Cash or cash equivalent $5,833.00 General
07/01/2021 Emergent BioSolutions Inc. Consulting Fee Cash or cash equivalent $5,833.00 General
07/01/2021 Emergent BioSolutions Inc. Consulting Fee Cash or cash equivalent $5,833.00 General
07/01/2021 Emergent BioSolutions Inc. Consulting Fee Cash or cash equivalent $5,833.00 General

About Dr. Mark Gold, MD

Dr. Mark Gold, MD is a Addiction Medicine healthcare provider based in Gainesville, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1578504593.

According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Gold, MD has received a total of $533,982 in payments from pharmaceutical and medical device companies, with $30,000 received in 2023. These payments were reported across 265 transactions from 7 companies. The most common payment nature is "Consulting Fee" ($348,966).

Practice Information

  • Specialty Addiction Medicine
  • Location Gainesville, FL
  • Active Since 06/09/2006
  • Last Updated 10/18/2010
  • Taxonomy Code 207RA0401X
  • Entity Type Individual
  • NPI Number 1578504593

Products in Payments

  • Naloxone (Drug) $53,591
  • AxoGuard Nerve Protector (Device) $37,750
  • Narcan (Drug) $33,731
  • Avance Nerve Graft (Device) $30,259
  • MRIDIAN (Device) $11,982
  • AxoGuard Nerve Connector (Device) $4,683

Data Sources

Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.

Addiction Medicine Doctors in Gainesville